Medical Gas Regulation Review; Announcement of Public Meeting; Correction, 70248 [2013-28083]
Download as PDF
<![CDATA[
70248
Federal Register / Vol. 78, No. 227 / Monday, November 25, 2013 / Proposed Rules
includes the month we make the first
recurring monthly SSI benefit payment
to you following your period of
suspension or termination and
subsequent reinstatement of those
benefits.
■ 10. Revise § 416.1920 to read as
follows:
§ 416.1920
subpart.
Your appeal rights under this
(a) Your appeal rights to the State.
You have the right to appeal to the State
if you disagree with any of the State’s
actions regarding reimbursement of the
interim assistance. You are not entitled
to a Federal hearing to appeal the State’s
actions regarding reimbursement for
interim assistance.
(b) Your appeal rights to us. You have
the right to appeal to us, in accordance
with subpart N of this part—
(1) The amount of your retroactive SSI
benefit payments we withheld from you;
(2) The amount of your retroactive SSI
benefit payments we sent to the State to
reimburse the State for interim
assistance it paid to you; and
(3) The amount of your retroactive SSI
benefit payments due to you after we
reimbursed the State for interim
assistance it paid to you.
§ 416.1922
[Removed and Reserved]
11. § 416.1922 is removed and
reserved.
■
Programs, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20993–0002,
301–796–3519, FAX: 301–847–8753,
email: Mary.Gross@fda.hhs.gov; or
Christine Kirk, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Silver Spring, MD
20993–0002, 301–796–2465, FAX: 301–
847–8440, email:
Christine.Kirk@fda.hhs.gov; or Urvi
Desai, Center for Veterinary Medicine,
Food and Drug Administration, 7500
Standish Pl., Rockville, MD 20855,
email: Urvi.Desai@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In the
Federal Register of Friday, November 1,
2013, in FR Doc. 2013–26056, on page
65588 the following corrections are
made:
1. In the third column, in the last
sentence of the second paragraph under
Registration and Requests for Oral
Presentations, ‘‘https://www.fda.gov/
Drugs/NewEvents/ucm370351.htm’’ is
corrected to read ‘‘https://www.fda.gov/
Drugs/NewsEvents/ucm370351.htm’’.
2. In the third column, in the first
sentence of the third paragraph under
Registration and Requests for Oral
Presentations, ‘‘https://www.fda.gov/
Drugs/NewEvents/ucm370351.htm’’ is
corrected to read ‘‘https://www.fda.gov/
Drugs/NewsEvents/ucm370351.htm’’.
Dated: November 19, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–28034 Filed 11–22–13; 8:45 am]
BILLING CODE 4191–02–P
[FR Doc. 2013–28083 Filed 11–22–13; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4160–01–P
Food and Drug Administration
21 CFR Chapter I
ENVIRONMENTAL PROTECTION
AGENCY
[Docket No. FDA–2013–N–0001]
40 CFR Parts 52 and 69
Medical Gas Regulation Review;
Announcement of Public Meeting;
Correction
[EPA–R09–OAR–2013–0697; FRL–9902–75–
Region 9]
AGENCY:
Food and Drug Administration,
HHS.
Notice of public meeting;
correction.
ACTION:
The Food and Drug
Administration is correcting a document
that appeared in the Federal Register of
November 1, 2013 (78 FR 65588). The
document announced a public meeting
entitled ‘‘Medical Gas Regulation
Review.’’ The document was published
with an incorrect Web site. This
document corrects that error.
DATES: Effective November 25, 2013.
FOR FURTHER INFORMATION CONTACT:
Mary Gross, Office of Executive
emcdonald on DSK67QTVN1PROD with PROPOSALS
SUMMARY:
VerDate Mar<15>2010
17:24 Nov 22, 2013
Jkt 232001
Approval and Promulgation of
Implementation Plans; Commonwealth
of the Northern Mariana Islands;
Prevention of Significant Deterioration;
Special Exemptions From
Requirements of the Clean Air Act
Environmental Protection
Agency (EPA).
ACTION: Proposed rule.
AGENCY:
Under the Clean Air Act, EPA
is proposing to disapprove the state
implementation plan (SIP) for the
Commonwealth of the Northern Mariana
Islands (CNMI) with respect to
prevention of significant deterioration
(PSD), and to incorporate by reference
the Federal PSD regulations into the
SUMMARY:
PO 00000
Frm 00009
Fmt 4702
Sfmt 4702
applicable CNMI plan. EPA is also
proposing to approve a petition by
CNMI for an exemption of the
applicable PSD major source baseline
date and trigger date under Federal PSD
regulations, and to establish an alternate
date, January 13, 1997, as the major
source baseline date and trigger date in
CNMI. EPA is also proposing to make
certain corrections that were made in
previous rulemakings. This action
would establish the Federal PSD
regulations as a basic element of the
CNMI implementation plan and,
through the exemption, would establish
January 13, 1997 as the major source
baseline date (and trigger date) under
the PSD program in CNMI for sulfur
dioxide, PM10 and nitrogen dioxide.
DATES: Comments must be received on
or before December 26, 2013. Request
for a public hearing must be received by
December 10, 2013. If we receive a
request for a public hearing, we will
publish information related to the
timing and location of the hearing and
the timing of a new deadline for public
comments.
ADDRESSES: Submit comments,
identified by docket number EPA–R09–
OAR–2013–0697, by one of the
following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the on-line
instructions.
• E-Mail: rios.gerardo@epa.gov.
• Mail or Deliver: Gerardo Rios
(AIR–3), U.S. Environmental Protection
Agency Region IX, 75 Hawthorne Street,
San Francisco, CA 94105.
Instructions: All comments will be
included in the public docket without
change and may be made available
online at www.regulations.gov,
including any personal information
provided, unless the comment includes
Confidential Business Information (CBI)
or other information whose disclosure is
restricted by statute. Information that
you consider CBI or otherwise protected
should be clearly identified as such and
should not be submitted through
www.regulations.gov or email. The
www.regulations.gov portal is an
‘‘anonymous access’’ system, and EPA
will not know your identity or contact
information unless you provide it in the
body of your comment. If you send
email directly to EPA, your email
address will be automatically captured
and included as part of the public
comment. If EPA cannot read your
comment due to technical difficulties
and cannot contact you for clarification,
EPA may not be able to consider your
comment.
Docket: The index to the docket for
this action is available electronically at
E:\FR\FM\25NOP1.SGM
25NOP1
]]>Agencies
[Federal Register Volume 78, Number 227 (Monday, November 25, 2013)]
[Proposed Rules]
[Page 70248]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-28083]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Chapter I
[Docket No. FDA-2013-N-0001]
Medical Gas Regulation Review; Announcement of Public Meeting;
Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public meeting; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration is correcting a document that
appeared in the Federal Register of November 1, 2013 (78 FR 65588). The
document announced a public meeting entitled ``Medical Gas Regulation
Review.'' The document was published with an incorrect Web site. This
document corrects that error.
DATES: Effective November 25, 2013.
FOR FURTHER INFORMATION CONTACT: Mary Gross, Office of Executive
Programs, Food and Drug Administration, 10903 New Hampshire Ave.,
Silver Spring, MD 20993-0002, 301-796-3519, FAX: 301-847-8753, email:
Mary.Gross@fda.hhs.gov; or Christine Kirk, Center for Drug Evaluation
and Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Silver Spring, MD 20993-0002, 301-796-2465, FAX: 301-847-8440, email:
Christine.Kirk@fda.hhs.gov; or Urvi Desai, Center for Veterinary
Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville,
MD 20855, email: Urvi.Desai@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In the Federal Register of Friday, November
1, 2013, in FR Doc. 2013-26056, on page 65588 the following corrections
are made:
1. In the third column, in the last sentence of the second
paragraph under Registration and Requests for Oral Presentations,
``https://www.fda.gov/Drugs/NewEvents/ucm370351.htm'' is corrected to
read ``https://www.fda.gov/Drugs/NewsEvents/ucm370351.htm''.
2. In the third column, in the first sentence of the third
paragraph under Registration and Requests for Oral Presentations,
``https://www.fda.gov/Drugs/NewEvents/ucm370351.htm'' is corrected to
read ``https://www.fda.gov/Drugs/NewsEvents/ucm370351.htm''.
Dated: November 19, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-28083 Filed 11-22-13; 8:45 am]
BILLING CODE 4160-01-P
